Comparator Sourcing Market Global Report 2026

The comparator sourcing market size has grown strongly in recent years. It will grow from $1.81 billion in 2025 to $1.95 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to limited availability of standardized reference products, high dependency on innovator drug samples for comparison, fragmented global regulatory frameworks for drug validation, rising demand for generic drug approvals, growth in pharmaceutical r&d outsourcing.

The comparator sourcing market size is expected to see strong growth in the next few years. It will grow to $2.63 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing complexity of biologics and biosimilar development, expansion of precision medicine and targeted therapies, rising adoption of advanced analytical testing technologies, stronger regulatory harmonization across regions, growth in global clinical trial networks and decentralized research. Major trends in the forecast period include rising demand for regulatory grade reference standards in pharmaceutical development, increasing outsourcing of comparator sourcing to contract research organizations, growing complexity of bioequivalence and analytical testing requirements, expansion of global clinical trial activities across emerging markets, increasing adoption of standardized quality validation frameworks in drug development.

The expansion of clinical trials is expected to propel the growth of the comparator sourcing market going forward. Clinical trials refer to carefully designed research studies conducted on human participants to evaluate the safety, effectiveness, and side effects of new medical treatments, drugs, or medical devices before they are approved for public use. The expansion of clinical trials is driven by increasing demand for new and more effective treatments for chronic and complex diseases, along with rising investments by pharmaceutical and biotechnology companies in drug development and regulatory approvals. Comparator sourcing supports clinical trials by ensuring the availability of high-quality equivalent reference treatments that enable accurate comparisons between investigational drugs and standard-of-care therapies, thereby improving study validity, regulatory compliance, and the reliability of clinical outcomes. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, the number of pharmaceutical industry trials launched in the UK increased for the second consecutive year, rising from 411 in 2022 to 426 in 2023. Therefore, the expansion of clinical trials is driving the growth of the comparator sourcing market.

Leading companies operating in the comparator sourcing market are focusing on developing innovative initiatives, such as centralized comparator drug sourcing programs, to improve clinical trial efficiency, reduce procurement delays, and ensure reliable access to reference biologics required for biosimilar development. Centralized comparator drug sourcing programs are integrated systems that manage procurement and supply of reference drugs for clinical trials, helping ensure timely access, regulatory compliance, and smoother biosimilar development. For example, in February 2026, VRC Medical Services, a US-based pharmaceutical company, launched a dedicated comparator support program designed to help biosimilar clinical trials overcome sourcing and supply chain constraints. The program centralizes comparator sourcing, compliance documentation, and trial-specific logistics into a unified framework, enabling faster procurement timelines and reducing risks linked to limited availability of reference biologics. It supports access to high-cost therapies such as rituximab, trastuzumab, bevacizumab, infliximab, and adalimumab, which are critical for biosimilar trials in oncology and autoimmune disease areas, ultimately helping accelerate biosimilar development and improve market competition in high-cost drug categories.

In December 2024, Novo Holdings A/S, a Denmark-based life sciences investment company, acquired Catalent Inc. for $16.5 billion. Through this acquisition, Novo Holdings A/S aimed to strengthen its global pharmaceutical manufacturing and contract development capabilities by integrating Catalent’s large-scale drug development, clinical supply, and advanced drug delivery technologies, thereby enhancing supply chain capacity and supporting the growing demand for biologics, injectables, and specialty medicines. Catalent Inc. is a US-based contract development and manufacturing organization (CDMO) that specializes in providing comprehensive global comparator sourcing services for clinical trials.

Major companies operating in the comparator sourcing market are Thermo Fisher Scientific Inc.; IQVIA Inc.; ICON Public Limited Company; Eurofins Scientific SE; Piramal Pharma Limited; Almac Group Limited; Wasdell Group Limited; Clinigen Group plc; Inceptua Group B.V.; Ancillare LP; Veristat LLC; BAP Pharma Holding Limited; Oximio Group Limited; Tanner Pharma Group Limited; Spring BioSolution Ltd.; N-SIDE S.A.

North America was the largest region in the comparator sourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the comparator sourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the comparator sourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The comparator sourcing market includes revenues earned by entities by providing services such as identification and procurement of reference products, regulatory-grade comparator supply, cold-chain logistics and distribution, authentication and traceability management, quality verification, documentation and compliance support, and inventory management of comparator materials. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The comparator sourcing market research report is one of a series of new reports that provides comparator sourcing market statistics, including comparator sourcing industry global market size, regional shares, competitors with a comparator sourcing market share, detailed comparator sourcing market segments, market trends and opportunities, and any further data you may need to thrive in the comparator sourcing industry. This comparator sourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.